Short answer
REGENXBIO Inc. (RGNX) filed an 8-K current report with the SEC on July 20, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). $107.8M expected net proceeds from equity offering, strengthening funding for operations and pipeline development.
REGENXBIO Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- $107.8M expected net proceeds from equity offering, strengthening funding for operations and pipeline development
- 10,003,889 shares sold at $9.00 plus 1,111,111 pre-funded warrants at $8.9999
- Underwriters exercised full 30-day option for 1,667,250 additional shares, increasing dilution versus initial offering
- Pre-funded warrants carry $0.0001 exercise price, no expiration and no voting rights before exercise
- Offering expected to close July 20, 2026, subject to customary conditions
Item EX-99.1 · Exhibit EX-99.1
- $100.0M gross proceeds targeted through 10,003,889 shares at $9.00 and 1,111,111 pre-funded warrants at $8.9999
- Capital raise supports REGENXBIO’s late-stage gene-therapy pipeline but creates substantial equity dilution
- Underwriters hold a 30-day option for 1,667,250 additional shares, potentially increasing dilution and proceeds
- Offering expected to close July 20, 2026, subject to customary conditions
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other REGENXBIO Inc. 8-K filings
Get the next RGNX 8-K as it lands
Follow RGNX for push alerts, or ask the research agent what this filing means.